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Warren S. Joseph, DPM, FIDSA,a and Benjamin A. Lipsky, MD, FACP, FIDSA, FRCP,b Philadelphia, Pa;
and Seattle, Wash
Diabetic foot infections are a common and often serious problem, accounting for a greater number of hospital bed days
than any other complication of diabetes. Despite advances in both antibiotic therapy and surgical management, these
infections continue to be a major risk factor for amputations of the lower extremity. Although a number of wound size
and depth classification systems have been adapted for use in codifying diabetic foot ulcerations, none are specific for
infection. In 2003, the International Working Group on the Diabetic Foot developed guidelines for managing diabetic
foot infections, including the first severity scale specific for these infections. The following year, the Infectious Diseases
Society of America (IDSA) published their Diabetic Foot Infection Guidelines. In this article, we review some of the
critical points from the Executive Summary of the IDSA document and provide a commentary following each issue to
update the reader on any pertinent changes that have occurred since the publication of the original document in 2004.
The importance of a multidisciplinary limb salvage team, apropos this special joint issue of the American Podiatric
Medical Association and the Society for Vascular Surgery, cannot be overstated. (J Vasc Surg 2010;52:67S-71S.)Until 20 years ago, what little literature there was
available on treating infections of the foot in persons with
diabetes suggested that: almost all were polymicrobial;
gram-negative bacilli and obligate anaerobes were frequent
pathogens; virtually all such patients needed to be hospital-
ized; and they should be treated with parenteral, broad-
spectrum antibiotic therapy. Studies published since 1990
have demonstrated that most of these assertions were at
least exaggerations, if not myths. With the accumulating
case series and investigations on treatment of diabetic
foot infections (DFIs), especially randomized clinical
trials and carefully conducted microbiological studies, by
the early 2000s, it was time for convening experts in the
field to develop evidence-based guidelines on diagnosing
and treating DFIs.
In 2003, the International Working Group on the
Diabetic Foot (IWGDF) appointed a committee that
drafted DFI guidelines1 that were approved by members
from over 60 participating countries and subsequently pub-
lished and distributed in multiple languages on DVD (www.
iwgdf.org). The following year, the Infectious Diseases Soci-
ety of America (IDSA) empanelled an expert committee to
draft diabetic foot infection clinical guidelines that were pub-
lished in 2004.2 These included an infection severity classifi-
cation scale that was subsequently validated and shown to
predict clinical outcomes.3 These documents, taken together,
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doi:10.1016/j.jvs.2010.06.010represent the most comprehensive multinational attempt to
codify a treatment approach to a condition that contributes to
71,000 lower extremity amputations per year in the United
States alone (www.diabetes.org). Although an updated set of
DFI Guidelines is slated to be published by the IDSA Com-
mittee sometime in 2010, and several new studies specifically
investigating antibiotic treatment of DFIs have been pub-
lished in the past 6 years,4 many of the original points pre-
sented in theExecutive Summaryof theoriginal document are
still valid and deserving of review. Furthermore, the validated
severity classification scale is now widely accepted and used to
classify patients enrolled in DFI studies and will remain un-
changed in the updated document.
SEVERITY SCALE
Many classification systems have been developed to
categorize diabetic foot wounds (especially ulcerations),
some of which include the presence or absence of infection.
None of these, however, have specifically classified the
severity of infection. Probably the most recognized, and
most venerable, system was that proposed by Wagner.5 In
this classification with four grades, more useful as a descrip-
tor of size and depth of a wound, the presence of an
infection is not considered until a Grade III ulceration,
which is described as a deep ulcer with abscess, osteomyeli-
tis, or joint sepsis. It is reasonable to ask, why can’t a less
extensive Grade 0, I, or II ulcer become infected? A newer,
validated system first proposed by investigators at the
University of Texas diabetic foot group is a derivation of
the Wagner scheme.6 This system includes infection as a
comorbidity modifier that can be added to any wound
depth category, but it does not specify the severity of the
infection.
In order to address the lack of an adequate severity
score for DFI, the IWGDF and the IDSA have each devel-
oped a mostly interchangeable, four level grading system
specifically for infection (Table I). The presence of infec-
tion in a foot wound is defined clinically, not by a positive
culture. Ulcerations are classified as either uninfected (lack-
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infected, with a severity of mild, moderate, or severe. The
differentiation between these categories is based on clinical
signs and symptoms, thus corroborating the importance of
making a clinical diagnosis of infection, as spelled out in
point #5 of the Executive Summary described below. This
scale has been validated in a prospective observational study
published by Lavery et al.3 When applied to 1666 patients
with a foot ulceration, there was a significant increase in
rates of hospitalization and lower extremity amputation
with increased severity of the infection. These classification
systems have now been widely accepted and are being
employed in academic and clinical circles. Some clinicians
Table I. Clinical classification schemes (Infectious Disease
Group on the Diabetic Foot [IWGDF]) for a diabetic foot
Clinical manifestations of infection
Wound lacking purulence or any manifestations of inflammation
Presence of purulence or 2 manifestations of inflammation (pain
warmth, or induration), but any cellulitis/erythema extends 2
and infection is limited to the skin or superficial subcutaneous t
complications or systemic illness.
Infection (as defined above) in a patient who is systemically well a
but which is associated 1 of the following characteristics: cellu
lymphangitic streaking, spread beneath the superficial fascia, de
gangrene, and involvement of muscle, tendon, joint, or bone.
Infection in a patient with signs or symptoms of systemic toxicity
leukocytosis) or metabolic instability (eg, tachycardia, hypotens
vomiting, acidosis, severe hyperglycemia, or azotemia)
aThe presence of critical ischemia of the affected limb often increases the se
bInternational Consensus on the Diabetic Foot PEDIS system: perfusion, e
Table II. Suggested antibiotic regimens for diabetic foot
Agent(s) Mild
Advised route Oral for mos
Dicloxacillin 
Clindamycin 
Cephalexin 
Trimethoprim-sulfamethoxazole 
Amoxicillin/clavulanate 
Levofloxacin 
Cefoxitin
Ceftriaxone
Ampicillin/sulbactam
Linezolida  aztreonam
Ertapenem
Cefuroxime  metronidazole
Ticarcillin/clavulanate
Piperacillin/tazobactam
Levofloxacin or ciprofloxain  clindamycin
Imipenem-cilastatin
Vancomycina  ceftazidime  metronidazole
Similar agents of the same class may be substituted. Some of these regimens m
only linezolid is currently specifically approved for diabetic foot infections.
Reprinted from Lipsky et al.2
aWhere methicillin-resistant Staphylococcus aureus infection is proven or likehave taken to combining systems that rate the size/depthof a wound, with infection severity (eg, “the patient pre-
sents with a University of Texas 2B wound with an IDSA
category moderate infection”). One of the benefits of the
infection severity scheme is that it can be used to help select
an appropriate antibiotic regimen for DFIs, as shown in
Table II.
EXECUTIVE SUMMARY REVIEW
The IDSA DFI guidelines contained a 19-point Exec-
utive Summary with the key recommendations for diagnos-
ing and treating these infections. The recommendations
still remain valid and are critical to a successful approach to
managing DFIs. We will address a few of the most impor-
ciety of America [IDSA] and International Working
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xtending 2 cm,
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ever, chills,
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Severe 4
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size, depth/tissue loss, infection, and sensation.
tions, based on clinical severity
Moderate Severe
Oral or parenteral, based on clinical
situation and agent(s) selected
Intravenous, at least
initially


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document. The original text is in bold italicized print,
followed by our commentary.
2. Diabetic foot infections require attention to local
(foot) and systemic (metabolic) issues and coordinated
management, preferably by a multidisciplinary foot-
care team. The teammanaging these infections should
include, or have ready access to, an infectious diseases
specialist or a medical microbiologist. Apropos this
special issue jointly published by the American Podiat-
ric Medical Association and the Society for Vascular
Surgery, the concept of a multidisciplinary team ap-
proach cannot be overstated. The team requires mem-
bers trained in the skill set necessary for limb salvage
and includes those concentrating on not only the
anatomic disturbances of the lower extremity but also
the perfusion to the limb. This approach (ie, care for
the diabetic foot wound by at least an irreducible team
of a foot specialist and a vascular surgeon) is aptly
named the “toe and flow” concept (Armstrong, DA
personal communication), an issue recognized in #14
below.
4. Aerobic gram-positive cocci (especially Staphylococcus
aureus) are the predominant pathogens in diabetic
foot infections. Patients who have chronic wounds, or
who have recently received antibiotic therapy, may
also be infected with gram-negative rods, and those
with foot ischemiaorgangrenemayhave obligateanaer-
obic pathogens. It has become increasingly clear that
Staphylococcus aureus, including methicillin-resistant
strains (MRSA), and Streptococcus spp, most oftenGroup
B, are the primary pathogens in most DFI. A number of
studies have shown that antibiotic therapy directed at just
these organisms can be successful, even when culture
results demonstrate various other gram-negative bacteria
or obligate anaerobes. This has led to the promulgation
of the “Head of the Snake” concept—the aerobic gram-
positive bacteria constitute the crucial head of the snake,
while other isolated organisms are part of the body. If
antibiotic therapy is directed at the primary organisms,
thereby “cutting off the head” of the snake, the residual
“body” would die. Thus, antibiotic therapy can often be
narrowly targeted at only aerobic gram-positive cocci.
5. Wound infections must be diagnosed clinically on the
basis of local (and occasionally systemic) signs and
symptoms of inflammation. Laboratory (including
microbiological) investigations are of limited use for
diagnosing infection, except in cases of osteomyelitis.
This point represents a cultural shift away from oft-
practiced technology- (mostly imaging) based ap-
proach to diagnosis. In order to diagnose infection in
a diabetic foot wound, the patient should present with
at least two of the clinical signs and symptoms of
inflammation including; erythema, edema, warmth,
tenderness, induration, or pain. Cultures should be
obtained, not to diagnose the infection, but rather to
determine which organism is causing the clinicallydiagnosed infection in order to aid in antibiotic selec-
tion. A recent IWGDF consensus statement on dia-
betic foot osteomyelitis suggests that culture-based
diagnosis and treatment are likely the best predictors of
a positive outcome.7 Even in cases of osteomyelitis, the
role of diagnostic imaging studies has been recently
challenged. Currently, magnetic resonance imaging is
the best imaging study for defining both soft tissue and
bone infections.8 Other studies have been investi-
gated, however, with positron emission tomography
(FDG-PET) combined with computed tomography
scanning being the most promising.9
9. Available evidence does not support treating clini-
cally uninfected ulcers with antibiotic therapy. Anti-
biotic therapy is necessary for virtually all infected
wounds, but it is often insufficient without appropri-
ate wound care. Inappropriate use of antibiotics leads
to bacterial resistance. This observation has gained
greater importance with the development of resistance
of the common gram-positive pathogens, especially
MRSA.10,11 An increasing threat of treating soft tissue
infections, including DFI, is the varying levels of tol-
erance of formerly susceptible microorganisms to van-
comycin.12 This can take the form of just increasing
minimum inhibitory concentrations (“MIC creep”) or
frank resistance (vancomycin-resistant S. aureus, or
VRSA). In fact, the first two reported cases of VRSA13
back in 2002 were isolated from diabetic foot wounds.
With advances in the agents available for antibiotic
treatment of these resistant gram-positive organisms
has come a newer threat (eg, multi-drug resistant
(MDR) gram-negative bacteria). Organisms, such as
species ofKlebsiella and Proteus, once relatively suscep-
tible to a wide range of antibiotics, now may produce
extended-spectrum beta-lactamases (ESBL) or carbap-
enemases, rendering them resistant to most commonly
used drugs.14 A major reason for the emergence of
these resistant organisms is inappropriate, typically un-
necessary, and overlong, antibiotic treatment.
10. Select an empirical antibiotic regimen on the basis of
the severity of the infection and the likely etiologic
agent(s). Therapy aimed solely at aerobic gram-
positive cocci may be sufficient for mild-to-moderate in-
fections in patients who have not recently received
antibiotic therapy. Broad-spectrum empirical therapy
is not routinely required but is indicated for severe
infections, pending culture results and antibiotic sus-
ceptibility data. Take into consideration any recent
antibiotic therapy and local antibiotic susceptibility
data, especially the prevalence of methicillin-resistant
S. aureus (MRSA) or other resistant organisms. De-
finitive therapy should be based on both the culture
results and susceptibility data and the clinical re-
sponse to the empirical regimen. The previously dis-
cussed “head of the snake” paradigm addresses initiat-
ing antibiotic therapy aimed principally (if not solely)
at aerobic gram-positive organisms for many DFI.
Even the 2004 Guidelines acknowledged the increas-
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worsened in most parts of the world. At the time the
Guidelines were prepared, clinical trials specifically
looking at antimicrobial management of DFI were
sparse, and rates of MRSA isolation were 10% or less.
More recent work has shown that these rates are in-
creasing.15 In some institutions,MRSA has supplanted
methicillin-susceptible S. aureus (MSSA) as the pri-
mary pathogen isolated in DFI. This raises the impor-
tant question: When should empiric MRSA coverage
be instituted? As stated in the summary point, the
decision to cover MRSA should be based on knowl-
edge of local prevalence, but at what “breakpoint” is
the decision made? Unfortunately, there are no hard
(or easy) and fast rules. The severity of the infection
along with the risk tolerance of the clinician should
each probably play a role. For mild infections, clini-
cians may tolerate a higher local prevalence or risk of
MRSA infection before initiating empiric MRSA ther-
apy, since the patient may do well with local wound
care regardless of whether or not the organism is
covered. However, for moderate to severe infections,
the threshold for initiating anti-MRSA therapy should
be lower (eg, an expected prevalence of 10%) given
the potential for serious sequelae if aggressive antibi-
otic therapy is not initiated. This has given rise to the
concept of “escalation” or “de-escalation” therapies
for empiric MRSA coverage. If the organism is not
empirically covered, the clinician can always “escalate”
(broaden the spectrum) the choice of therapeutic
agents to include MRSA once initial culture results are
received. Likewise, if there is a greater concern that it
may be present, broader spectrum empiric coverage is
begun with the option of “de-escalation” (narrowing
the spectrum) if cultures reveal only susceptible organ-
isms. The availability of several new anti-MRSA anti-
biotic agents has made covering this organism easier
than it was a decade ago.16
14. Seek surgical consultation and, when needed, inter-
vention for infections accompanied by a deep abscess,
extensive bone or joint involvement, crepitus, substan-
tial necrosis or gangrene, or necrotizing fasciitis.
Evaluating the limb’s arterial supply and revascular-
izing when indicated are particularly important.
Surgeons with experience and interest in the field
should be recruited by the foot-care team, if possible.
This final point is at the heart of the entire “toe and
flow” concept. By the definition used by the US Food
and Drug Administration, a complicated skin and skin
structure infection (cSSSI) is one in which the patient
either has a significant underlyingmedical comorbidity
or an immunocompromising disease; in these cases,
the potential for greater severity of the infection may
require more aggressive surgical approaches (eg, inci-
sion and drainage or resection of infected and necrotic
tissue). Although appropriate antibiotic therapy can be
critical in achieving optimal outcomes, for many mod-
erate to severe DFI, surgical intervention can be key tolimb salvage. A recent consensus statement from the
IWGDF7 classifiedDFI surgery as being “urgent” only
in cases of necrotizing or deep soft tissue infections,
major abscess, or gangrene. “Nonurgent” surgery may
be needed when there is risk of significant compromise
of the soft tissue envelope, loss of mechanical function,
or if the degree of bone involvement is life- or limb-
threatening. However, none of this “toe” surgery can
be accomplished without adequate “flow” to the limb.
Likewise, antibiotic therapy of the “toe” infection
needs adequate “flow” to achieve therapeutic levels (of
antibiotic and leukocytes) in the target infected tissues.
Thus, a full circle is completed from the first executive
summary review point to the last. A team approach is
required, with specialists who are interested in foot
infections and who possess the necessary skill set to
succeed at diabetic limb salvage. Optimal outcomes for
patients presenting with DFIs have repeatedly been
shown to depend on care by a team of specialists, includ-
ing those with training in podiatric and vascular surgery
along with infectious diseases, diabetes, wound care, and
internal medicine. To this end, the IDSA DFI Commit-
tee has been expanded to include stakeholders from
specialties across the spectrum of diabetic foot care,
including podiatric surgery and vascular surgery. All of
these voices will be included in the 2010 update.
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